RECRUITING

Immunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a prospective, observational study to investigate molecular mechanisms mediating the systemic inflammatory process, and changes to metabolism, and their impact on brain injury, survival, and functional outcomes after cardiac arrest. Investigators have shown that cardiac arrest induces changes in the numbers and properties of circulating immune cells, shifting the balance towards a pro-inflammatory phenotype and there is increased interest in the inflammatory pathways and the signaling mechanisms through which they are modulated. Participants will undergo blood sampling during 7 days following cardiac arrest, and analyses performed. Patient characteristics, clinical circumstances, and outcomes will be recorded and their associations with these inflammatory pathways characterized.

Official Title

Immunoinflammatory and Metabolic Responses in Post Cardiac Arrest Syndrome (PCAS)

Quick Facts

Study Start:2016-01
Study Completion:2026-03-20
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02664831

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Aged 18 years or older
  2. * Admitted to the intensive care unit after cardiac arrest episode
  3. * Unresponsive after resuscitation
  1. * Moribund / actively dying at the time of evaluation
  2. * Informed consent cannot be obtained within 24 hours of resuscitation
  3. * Hemoglobin less than 7.0 g/dL, active high-volume bleeding, or requiring a transfusion

Contacts and Locations

Study Contact

David B Seder, MD
CONTACT
207-662-2179
david.seder@mainehealth.org
Sergey Ryzhov, PhD
CONTACT
sergey.ryzhov@mainehealth.org

Principal Investigator

Sergey Ryzhov, MD, PhD
PRINCIPAL_INVESTIGATOR
MaineHealth Institute for Research
David B Seder, MD
PRINCIPAL_INVESTIGATOR
MaineHealth

Study Locations (Sites)

Maine Medical Center
Portland, Maine, 04102
United States

Collaborators and Investigators

Sponsor: MaineHealth

  • Sergey Ryzhov, MD, PhD, PRINCIPAL_INVESTIGATOR, MaineHealth Institute for Research
  • David B Seder, MD, PRINCIPAL_INVESTIGATOR, MaineHealth

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-01
Study Completion Date2026-03-20

Study Record Updates

Study Start Date2016-01
Study Completion Date2026-03-20

Terms related to this study

Keywords Provided by Researchers

  • cardiac arrest
  • inflammation
  • immune
  • neuregulin
  • lymphocyte
  • neutrophil
  • brown adipose

Additional Relevant MeSH Terms

  • Cardiac Arrest
  • Inflammation
  • Obesity